Numerous other studies on changes in KP metabolites have confirmed the activation of KP in MS: Mancuso et al. (2015) verified an increased expression of IDO-1 (the first enzyme of the KP) in patients with RRMS. Here, IDO1 is linked to myeloid sarcoma.